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Abstract
Variations in gene promoter/enhancer activity in different muscle fiber types after gene transduction was noticed
previously, but poorly analyzed. The murine stem cell virus (MSCV) promoter drives strong, stable gene expression in
hematopoietic stem cells and several other cells, including cerebellar Purkinje cells, but it has not been studied in muscle.
We injected a lentiviral vector carrying an MSCV-EGFP cassette (LvMSCV-EGFP) into tibialis anterior muscles and observed
strong EGFP expression in muscle fibers, primary cultured myoblasts, and myotubes isolated from injected muscles. We also
generated lentiviral-mediated transgenic mice carrying the MSCV-EGFP cassette and detected transgene expression in
striated muscles. LvMSCV-EGFP transgenic mice showed fiber type-dependent variations in expression: highest in types I
and IIA, intermediate in type IID/X, and lowest in type IIB fibers. The soleus and diaphragm muscles, consisting mainly of
types I and IIA, are most severely affected in the mdx mouse model of muscular dystrophy. Further analysis of this promoter
may have the potential to achieve certain gene expression in severely affected muscles of mdx mice. The Lv-mediated
transgenic mouse may prove a useful tool for assessing the enhancer/promoter activities of a variety of different regulatory
cassettes.
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Introduction
A recombinant lentiviral vector is an efficient tool for delivering
genes to dividing and non-dividing cells [1,2,3]. Compared with
non-integrating vectors, the ability of lentiviral vectors to integrate is
an important advantage when targeting muscle diseases, such as
Duchenne muscular dystrophy (DMD) [4,5,6,7,8,9,10]. DMD
muscles lack the dystrophin protein, and dystrophin gene
replacement is expected to halt ongoing myofiber turnover. To
drive the transcription of various genes in gene therapy protocols,
several strong viral enhancer/promoters were used in previous
studies, including cytomegalovirus (CMV) [11,12,13], Raus sarco-
ma virus (RSV) [14,15,16], cytomegalovirus enhancer, chicken
beta-actin (CAG) promoter [16,17,18,19], murine stem cell virus
(MSCV) [16,17,20,21], mouse phosphoglycerate-kinase 1 (pGK)
[12,22,23], and elongation factor 1 (EF1) [12,24], which are
ubiquitous promoters derived from house keeping gene regulation
systems in mammalian cells. As the MSCV promoter drives gene
expression as strongly as the CMV promoter and achieves stable
gene expression in different type of cells, especially muscle fibers, we
previously used the MSCV promoter to regulate the expression of a
short version of the dystrophin gene in a lentiviral vector [6]. The
expression of therapeutic protein was detected in mdx muscles,
however it was a little weaker in some of the fibers than we expected.
Similarly, when we intramuscularly injected a lentiviral vector
containing an MSCV-EGFP cassette into murine skeletal muscles,
we observed a variety of EGFP expression levels [6]. The MSCV
promoter has also been used in the hematopoietic gene therapy field
[17,20], and was reported to be the best for viral-vector-mediated
gene delivery into cerebellar Purkinje cells in vivo [16]; nevertheless,
no other assessment of its tissue specificity was previously reported.
As the muscle creatine kinase gene (CK6) promoter, a muscle-
specific promoter [25], has fiber-type-dependent activity in murine
skeletal muscle when tested in AAV vectors [26,27], we
hypothesized that the observed weaknesses in MSCV promoter
activity might also depend on muscle fiber type. Murine skeletal
muscles are composed of four major fiber types: type I or slow-
twitch oxidative, IIA or fast-twitch oxidative glycolytic, IID/X or
fast-twitch intermediate glycolytic, and IIB or fast-twitch glycolytic
fibers. The fiber types can be distinguished by myosin-ATPase,
oxidative enzyme histochemistry, and nicotinamide adenine
dinucleotide tetrazolium reductase (NADH-TR) reactions [28],
and are related to two distinct physiological parameters: speed of
contraction and resistance to fatigue [29,30].
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Muscle fiber types with predominant promoter activity for
vector-mediated gene therapy have been noted but not yet
extensively studied. As we are interested in the usefulness of the
strong MSCV promoter to drive therapeutic genes, such as
dystrophin, in skeletal muscles, we have focused on the activity of the
MSCV promoter in skeletal muscles and cultured myotubes. To
explore the gene regulating ability of the MSCV promoter in
skeletal muscles, we tested lentiviral gene delivery methods with
intramuscular injection. Ikawa et al. previously reported that
lentiviral-mediated transgenic mice were easy to generate and
might be a useful tool for analyzing gene expression cassettes,
including enhancer/promoter gene regulation abilities [31].
Therefore, we also generated a transgenic mouse carrying the
MSCV-EGFP cassette using lentiviral-mediated gene delivery to
two-cell-stage embryos and performed detailed analyses of this
mouse, including the pattern of EGFP expression in skeletal
muscles.
Results
Titer of viral vectors
Before using the lentiviral vectors in in vivo and in vitro
experiments, we analyzed their ability to transduce 293D and
NIH3T3 cells [6]. The titer of the virus was estimated to be
5.0610822.06109 transduction units (TU)/ml in a series of
preparations (Figure 1, legend).
Variations in EGFP expression levels after intramuscular
injection of LvMSCV-EGFP
To determine whether the lentiviral vectors could efficiently
mediate transgene expression in mouse skeletal muscles under the
control of the MSCV promoter, we injected 5 ml of LvMSCV-
EGFP vector into the TA muscles of 3-day-old C57Bl/10 mice. By
4 weeks post injection, EGFP expression was observed in the
injected muscles. Although there were differences in the overall
expression levels in individual muscles, among the independent
injections, a differential expression could still be observed in the
various muscle fiber types. In particular, the type IID/X fibers,
which could be distinguished as darkly stained fibers with NADH-
TR and ATPase (pH 10.8) staining, expressed higher levels of
EGFP than did the type IIB fibers, which were lightly stained with
NADH-TR (Figure 2a).
EGFP expression in primary myoblasts and myotubes
cultured from the injected muscles
To test whether intramuscularly injected lentiviral vector
reached the myogenic progenitor cells in skeletal muscles, we
harvested injected muscles, digested them with collagenase, and
collected mononuclear cells to culture in dishes. Cells proliferated
well and then formed myotubes. About 10–40% of the myoblast
colonies were positive for EGFP. In the positive colonies, cells
continued this expression during the time that they fused and
formed myotubes (Figure 2b). Thus, primary cultured myoblasts
and myotubes highly expressed EGFP driven by the MSCV
promoter.
Efficiency and variation of EGFP expression in mice
derived from Lv-transduced embryos
To analyze MSCV promoter activity without the influence of
the variability we observed among the individual manual
injections, we transduced the lentiviral vectors into B6D2F1
mouse embryos and generated 8 transgenic mouse lines that
included lentiviral vector provirus genomes in their chromosomes.
From two-cell-stage embryos transduced with LvMSCV-EGFP,
17 F0 mice were born, of which 8 were positive for the for EGFP
transgene (genomic PCR analysis, Table S1). The mice were
sacrificed at 8–10 mo, and then analyzed by quantitative PCR to
determine the numbers of Lv-provirus copies inserted in the host
cell genomes. In this case, a mean of 2.7060.75 Lv-provirus copies
were stably integrated into the mouse genomes.
Type I and type IIA fibers contain the predominant EGFP
expression in LvMSCV-EGFP transgenic mouse lines
To analyze the EGFP expression levels in skeletal muscles, 10-
mm-thick frozen sections of the brachio-triceps, quadriceps, tibialis
anterior, gastrocnemius, and solius muscles from LvMSCV-EGFP
transgenic and wild type mice were observed under a fluorescence
microscope (Figure 3). The fiber types were determined by
NADH-TR staining, ATPase staining at pHs 10.8, 4.5, and 4.2
(Figure 3), and also confirmed with fiber type specific antibodies
(Method S1, Figure S1). Various EGFP expression levels were seen
at 488 nm. In the brachio-triceps, quadriceps, tibialis anterior, and
gastrocnemius muscles (fast twitch), which consist mainly of type
IIB and IID/X, there were EGFP expression, however a mosaic
pattern in the level of expression was observed: type IID/X fibers
showed higher expression than the type IIB fibers. In the soleus
muscles (slow twitch), which predominantly consist of type I and
type IIA fibers, almost all of the fibers strongly expressed EGFP as
well as NADH-TR. In both of the tibialis anterior and the soleus
muscle, the pattern of EGFP expression was almost identical to
that of the NADH-TR staining. Although there were still minor
variations in EGFP expression levels among the various mice due
to embryo transduction variation, all of the collected muscles
presented similar EGFP expression patterns (Figure 4).
These four different fiber types can be captured together in an
axial transverse section of the border of the gastrocnemius and
soleus muscles, making it easy to compare the EGFP expression
levels among them in the same section (Figure 5a). Quantitative
analysis of fluorescence intensity showed that the strongest signals
were in the type I (106.9261.25) and IIA (100.0961.62) fibers,
intermediate signals were in type IID/X fibers (87.3063.60), and
the weakest signals were in type IIB fibers (57.2961.71). There
were significant differences among these three groups (p,0.005,
Figure 5b).
Figure 1. Construction of a lentiviral vector. EGFP was packaged into the lentiviral vector under the control of an MSCV promoter. The titer of
the virus was estimated at about 1.06109 TU/ml. Y; packaging signal, RRE; HIV Rev response element, cPPT; HIV-1 central polypurine tract, MSCV;
murine stem cell virus promoter, EGFP; enhanced green fluorescence protein gene, PRE; human hepatitis virus post-transcriptional regulatory
element.
doi:10.1371/journal.pone.0016908.g001
Muscle Fiber Type-Predominant MSCV Promoter
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Discussion
In our examination of the usefulness of the MSCV promoter to
drive the expression of therapeutic genes, such as dystrophin, in skeletal
muscles [6], we focused on its activity in skeletal muscle tissue and
myotubes. In young mice given intramuscular injections of
LvMSCV-EGFP vector into the TA muscles, type IID/X fibers
expressed higher levels of EGFP than did type IIB fibers. Then, we
tested this MSCV-EGFP expression cassette in transgenic mice using
Lentiviral-mediated gene transduction into two-cell-stage embryos.
In the transgenic mice, EGFP expression was highest in type I and
type IIA muscle fibers; showed medium expression in type IID/X
fibers, and was lowest in type IIB fibers (summarized in Figure 6.)
When we observed the border area of the soleus and gastrocnemius
muscles, where all 4 fiber types are present in one section, expression
in type IID/X fibers was a little weaker than in the type I and type IIA
fibers. Together, these observations demonstrate that the activity of
the MSCV promoter exhibits fiber type predominance. These
differences in promoter activity might arise from the type of myosin
(fast or slow), amount of myoglobin, the degree of oxidative
phosphorylation that the fiber undergoes, or the reliance on the
glycolytic enzymes of oxidative metabolism to generate ATP.
Most murine skeletal muscles consist of mainly type IIB and
type IID/X fibers, although the soleus and diaphragm consist of
mainly type I and IIA muscle fibers [32,33]. In the mdx mouse,
tongue, heart, diaphragm, and soleus muscles exhibit the most
severe dystrophic changes, such as regeneration and degeneration
with fibrosis [34,35]. The diaphragm and soleus are among the
slowest of muscles in the mouse [36]. These observations suggest
that the susceptibility for dystrophin-related fiber damage may be
related to the fiber type predominance of each muscle, which may,
in turn, be due to their glycogen levels, the ratio of skeletal myosin
isoforms, or their frequency of movement. The diaphragm is also
one of the most severely affected muscles in DMD patients,
although some reports have suggested that mixed fiber type
muscles show more necrosis and subsequent regenerations of fast
fibers in biopsies from Psoas and Vastus lateralis muscles [37] or
type IIB fibers were affected in early stage of DMD boys [38]. As
nNOS is predominantly expressed in the type IIB fibers [39], the
loss of nNOS activity caused by the dystrophin deficiency is
considered to play an important role in the pathogenesis of muscle
degeneration in DMD, although there is discrepancy (difference)
of nNOS localization in muscle fiber types between human and
rodent skeletal muscles.
The mosaic expression patterns often observed with marker
genes (e.g., GFP or LacZ) may be due to the fiber type-specific
promoter activities of CMV, CAG, and CK6 promoters [26], as
was often shown in muscles following viral vector-based transduc-
tion. This activity variance is not negligible from the standpoint of
their applications. We have shown that the MSCV promoter
activity was stronger in type I and type IIA fibers found mainly in
slow twitch muscles. In other words, this promoter has a high
predilection for muscles that are susceptible to dystrophic damage.
Thus, as this promoter achieved long-term dystrophin expression
in the mdx mouse [6], it might be a candidate promoter for gene
therapy of murine muscular dystrophy models. On the other hand,
we consider that any fiber types without dystrophin expression
need to be treated by dystrophin gene replacement. At the very
Figure 2. Intramuscular injection of LvMSCV-EGFP into striated muscle. (a) Micrographs of serial sections from a lentiviral vector-transduced
skeletal muscle showing fluorescent EGFP expression and NADH-TR, HE, and ATPase staining (at pHs 10.8, 4.5, and 4.2). EGFP expression was strong in
the Type IID/X fibers (D), which can be distinguished by dark staining with NADH-TR and ATPase at pH 10.8, but weaker in type IIB fibers (B), which
are lightly stained in NADH-TR. There are a few type IIA fibers (A), darkly stained with NADH-TR and ATPase at pHs 10.8, 4.5, and 4.2, also brightly
positive for EGFP. Scale bar represents 100 mm. (b) Primary cultured myotubes isolated from LvMSCV-EGFP-injected TA muscles. Seven weeks after
transduction, muscle cells were isolated and cultured in F10C/15% HS/5 ng/ml with bFGF. EGFP-positive myotubes were observed after 7 days in
culture.
doi:10.1371/journal.pone.0016908.g002
Muscle Fiber Type-Predominant MSCV Promoter
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least, additional analyses should be carried out to provide further
details about the ‘ideal expression cassette’ for using it in the gene
therapy of muscular dystrophies, particularly in terms of
combining it with other muscle-specific promoters. A number of
studies have compared different versions of promoters/enhancers
derived from the muscle creatine kinase gene (MCK), such as CK6
[26] and CK7 [27]. Interestingly, those promoters showed
preferential activity in fast fiber types, rather than in the slow
fibers that we observed here with MSCV.
Regarding the safety issue of gene therapy using vector cassettes,
muscle tissue-specific promoters are considered to be advanta-
geous for eliminating transgene expression in other types of cells,
especially antigen presenting cells [40,41,42,43]. On the other
hand, we propose the idea of ‘‘the right promoter for the right
muscle’’. At this time there may be strengths and weaknesses in all
known promoters, which should be investigated and clarified.
From a clinical point of view, as the weakness of respiratory
muscles, including especially the diaphragm, are directly linked to
patient lifespan [44], they are important targets of therapeutic
approaches for DMD patients [45]. If the new candidate promoter
is also activated better in the diaphragm, it may be applicable for
gene or cell therapies targeting this muscle; although, an entire,
body-wide therapeutic gene expression might be the best choice
for DMD patients, if we could achieve it without safety problems.
As we have shown in this study, and also in a previous report
[31], Lv-mediated transgenic mice were efficiently generated by
infecting fertilized eggs with vesicular stomatitis virus envelope
protein (VSV-G)-pseudotyped lentiviral vectors. As shown in
Figure 4, there were still variable expression levels of the transgene
among the lines, probably due to the integrated proviral copy
number or variety of integration sites. Still, we have highlighted
the usefulness of promoter analysis using these transgenic mouse
lines. Although multiple proviral insertions make it difficult to
establish pure-breeding transgenic lines, this might be an
advantage for evaluating the nature of lentiviral vectors in vivo,
as the situation is more similar to that of clinical gene therapy.
Moreover, myofibers themselves may equalize heterogeneity of
copy numbers and insertion sites of provirus, because each
myofiber contains abundant myonuclei from each myoblast fusion.
In conclusion, we have shown that MSCV promoter activity in
skeletal muscle is fiber-type-dependent when delivered directly by
lentiviral infection as well as in transgenic mice generated by
lentiviral infection. Further analysis of this promoter may
determine the necessary components needed to direct the slow
muscle-dominant gene expression and that are capable of
coordinating with other muscle-specific expression cassettes for
therapeutic application. Moreover, the Lv-mediated transgenic
mouse may prove to be a useful tool for assessing the enhancer/
promoter activities of a variety of different regulatory cassettes.
Materials and Methods
Cell cultures
293D cells (human embryonic kidney cells, kindly provided by
Dusty Miller, Fred Hutchinson Cancer Research Center),
NIH3T3 cells, and C2C12 cells (both provided by RIKEN BRC
CELL BANK, Tukuba, Japan) were used. All cells were grown in
Dulbecco’s modified Eagle’s medium (DMEM; Invitrogen,
Carlsbad, CA) with 10% fetal bovine serum (HyClone, Logan,
Utah, USA), 50 U/ml penicillin, and 50 U/ml streptomycin
(Sigma, St. Louis, MO, USA). The cultures were incubated at
37uC in a humidified atmosphere containing 5% CO2.
Construction of lentiviral transfer vectors
Lentiviral vectors were constructed as described previously [6].
Transfer vectors were constructed by inserting the corresponding
coding sequences into the polylinker of the pRRL-cPPT-CMV-X-
PRE-SIN vector [46]. For a transfer vector, the human CMV
promoter was replaced with the MSCV promoter [47].
Lentiviral vector preparation and titration
Lentiviral vectors were generated as described previously [1,6].
VSV-G-pseudotyped lentiviral vectors were produced by co-
transfecting the appropriate plasmids into 293D cells, and purified
by ultracentrifugation as described [6,9,10,48]. The titer of viruses
Figure 3. Type I, IIA, and IID/X fiber-predominant EGFP
expression in the tibialis anterior and soleus muscles from
lentiviral-mediated MSCV-EGFP transgenic mouse. Micrographs
from serial-sectioned TA and soleus muscles from 3-month-old LvMSCV-
EGFP transgenic mice showing EGFP fluorescence, NADH-TR, ATPase (at
pHs 10.8, 4.5, and 4.2), and HE staining. In the TA muscle (left) dappled
EGFP expression is observed; EGFP expression in strongest in type IID/X
fibers (labeled D) and weaker in type IIB fibers (labeled B). The TA
muscle consists of mainly type IIB and IID/X fibers. On the other hand,
soleus muscles (right) consist mainly of type I and IIA fibers (labeled I
and A, respectively), both of which strongly express EGFP. The fiber
types were confirmed by NADH-TR, and ATPase (pH 10.8, 4.5 and 4.2)
staining of serial sections. The pattern of EGFP expression is almost
identical to that of NADH-TR staining. Scale bar represents 100 mm.
doi:10.1371/journal.pone.0016908.g003
Muscle Fiber Type-Predominant MSCV Promoter
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containing the reporter gene was measured by transducing 293D
and NIH3T3 cells with serial dilutions of vector preparations, and
also by quantitative RT-PCR methods [21], which were adjusted
with flow cytometry (FACS) data of a well-known titered control
EGFP vector (LvMSCV-EGFP) as previously described [6,9].
Briefly, 26105 cells were transduced with 0.05 ml of LvMSCV-
EGFP vector and cultured in fresh DMEM plus 10% fetal calf
serum (FCS, HyClone, Logan, Utah, USA) for 2 days before FACS
analysis in triplicate. 50% of the cells expressed EGFP in the
cultures. The titer of these vector stocks was estimated by measuring
viral p24 gag antigen using the HIV-1 p24 Antigen ELISA Assay kit
(ZeptoMetrix Corporation Inc., Buffalo, NY, USA).
Mouse strains
C57BL/10, C57BL/10 mdx (Central Institute for Experimental
Animals, Kawasaki, Japan) and B6D2F1 (Research Institute for Microbial
Diseases, Osaka University, Osaka, Japan) strains of mice were used. All
animal experiments were approved by the Kumamoto University
Committee on Animal Research (permit number C22-176) and the
Osaka University Committee on Animal Research (permit number
2589). The mice were housed in the Center for Animal Resources
and Development (CARD) of Kumamoto University in rooms that
were maintained at 2262uC, 50610% relative humidity, and a 12/
12 h light/dark cycle. They had free access to drinking water and
standard chow, and were sacrificed at 3 months.
Intramuscular injection with LvMSCV-EGFP
Vectors were injected into muscles as described previously [48].
Briefly, 2-day-old mice were put on ice to anesthetize with
hypothermia, and then injected with 5 ml of viral preparations
with titers of 1.06109 TU/ml into the right and left TA muscles.
Four weeks after intra-muscular administration, the TA muscles
were harvested; some were cryosectioned for histology, and some
were used for primary cultures.
Histological staining with H&E, NADH-TR, PAS, and
ATPase staining
Routine H&E, NADH-TR, and ATPase staining were
performed as described previously [30]. Briefly, the various fiber
types were determined by NADH-TR staining and differential
Figure 4. EGFP expression regulated by MSCV promoter in skeletal muscles following embryo transduction. Brachio-triceps,
quadriceps, tibialis anterior, gastrocnemius, and soleus muscles of 3 different mice (3093, 3094, and 3095) from independent embryo-transductions
were cryosectioned and observed under a fluorescence microscope. The average Lv-copy numbers (mean 6 SEM) are shown at the bottom. Each
section shows the expression of EGFP. Although the overall levels of EGFP expression varied among the three mice (transduction at the two-cell
embryo stage), they each displayed a similar fiber-type expression pattern. Scale bar represents 100 mm.
doi:10.1371/journal.pone.0016908.g004
Muscle Fiber Type-Predominant MSCV Promoter
PLoS ONE | www.plosone.org 5 March 2011 | Volume 6 | Issue 3 | e16908
ATPase staining at different preincubation pHs. ATPase at
pH 10.8 distinguishes type I (light staining) from type II (dark
staining) fibers; pH 4.5 distinguishes type I (dark staining) from IIA
(light staining) and IIB (medium staining) fibers; and pH 4.2
distinguishes IID/X (medium staining) from IIA or IIB (light
staining) fibers. The three preincubation reagents were (1) 20 mM
sodium barbital, 36 mM CaCI2, pH 10.8, (2) 50 mM sodium
acetate, 30 mM sodium barbital brought to pH 4.5 with HCI, and
(3) the same as (2) but adjusted to pH 4.2. The sections were
preincubated for 15 min at pH 10.8 and 5 min at the acid pHs.
After preincubation, the sections were incubated for 45 min in
20 mM sodium barbital, pH 9.5, containing 9 mM CaCl2 and
2.7 mM ATP; rinsed in 2 changes of 1% CaCl2 (1 min each);
immersed for 2 min in 2% CaCl2; and rinsed with several changes
of tap water. After staining with 1% (NH4)2S, the sections were
washed with several changes of tap water, dehydrated with
ethanol, cleared in xylene, and mounted in balsam.
Isolation and culturing of muscle mononuclear cells
Mononuclear cells were harvested from the TA hindlimb
muscles of LvMSCV-EGFP-injected mice at 2 mo, as well as from
the TA muscles of age-matched, wild type mice as a control for
Figure 5. MSCV-EGFP transgenic mice showed fiber type-dependent variations in EGFP protein expression. (a) The expression of EGFP
at the border of the gastrocnemius and soleus muscles, where all 4 fiber types, type I, type IIA, type IIB, and type IID/X (labeled I, A, B, and D,
respectively), are present. Each fiber type was confirmed by NADH-TR and ATPase (at pHs 10.8, 4.5, and 4.2) staining. Bar represents 100 mm. (b) Bar
graph showing the mean (+SEM) intensity levels of EGFP protein in each fiber type. Type I fibers and IIA fibers presented the strongest signals, type
IID/X fibers had intermediate expression levels, and type IIB fibers had the weakest. Except between type I and type IIA (*p = 0.03), there were
significant differences among the various fiber types (**p,0.005).
doi:10.1371/journal.pone.0016908.g005
Figure 6. Summary of the fiber type-dependent EGFP expression in LvMSCV-EGFP mediated transgenic mice. Levels of EGFP
expression and typical staining pattern of each muscle fiber type are summarized. The EGFP expression pattern was mostly identical to that of the
NADH-TR staining. Fiber types were determined by the ATPase stainings with different pHs (pH 10.8, 4.5, and 4.2). Colors reflect the staining colors on
muscle sections.
doi:10.1371/journal.pone.0016908.g006
Muscle Fiber Type-Predominant MSCV Promoter
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culturing as described previously [6]. Briefly, TA muscles were
excised, minced, and digested in phosphate buffered saline (pH 7.2
GIBCO, Invitrogen, Grand Island, NY) with final concentrations
of 1 mM CaCl2 and 0.2% collagenase II (Worthington Biochem-
ical Corporation, Lakewood, NJ) at 37uC for 45 min, and then
filtered through 70- and 40-mm nylon filters (BD Falcon, Franklin
Lakes, NJ). Mononuclear cells were cultured on 0.67% gelatin-
coated plates in medium containing F10 medium (GIBCO,
Invitrogen, Grand Island, NY) with 10 mM CaCl2 (F10C) plus
15% horse serum (GIBCO, Invitrogen, Grand Island, NY) and
5 ng/ml recombinant human basic FGF-2 (R&D systems,
Minneapolis, MN). At day 7, differentiation was induced by
rinsing the cultures and switching them to medium containing
F10C with 1.5% horse serum and 6 mg/ml insulin for 48 h,
followed by re-feeding with F10C with 15% horse serum and
insulin [6,49]. At day 14, cells were observed under a fluorescence
microscope (DP70-WPCXP, Olympus, Tokyo, Japan).
Treatment of embryos and generation of transgenic mice
Lentiviral transduction in two-cell-stage embryos was described
previously [31]. Briefly, B6D2F1 females were superovulated by
intraperitoneal injection of pregnant mare’s serum gonadotropin
(5 U) and 48 h later with human chorionic gonadotropin (5 U),
and then mated with B6D2F1 males. Two-cell-stage embryos were
collected from the oviducts of the copulated females 36 h after
injection of human chorionic gonadotropin. To remove the zona
pellucida, the embryos were placed in acidic Tyrode’s solution
[50] for 30 s to 1 min. After dissociation of the zona pellucidae
was confirmed, embryos were washed three times with kSOM [51]
and incubated at 37uC for 2.5 days in a 5-ml drop of kSOM
containing viral vectors at multiplicity of infection of 105.
Blastocysts developed from infected embryos were transferred
into 2.5 day pseudo-pregnant females [31]. The pups were
delivered via Caesarean section at pregnant day 20 (Table S1).
Detection of proviral DNA copies with PCR and Q-PCR
DNA was isolated using the DNeasy Blood & TissueFlexiGene
DNA kit (QIAGEN Science, Maryland, MD) from the tail tips of
weaned pups, and subjected to 40 rounds of PCR amplification
with primers EGFP for (59-GCCACCATGGTGAGCAAGGGC-
GAG-39) and EGFP rev (59-TCACCTTGATGCCGTTCTTCT-
39) to check the existence of the EGFP transgenes [31].
The number of proviruses per genome in transgenic lines was
determined by the Q-PCR method as described previously [21].
Briefly, diluted DNA was analyzed by real time PCR using probe
PRE (5-FAM AGCTCTCTCGACGCAGGACTCGGC-TAM-
RA-3) and primers F-PRE (5- ACCTGAAAGCGAAAGG-
GAAAC-3), R-PRE (5-CACCCATCTCTCTCCTTCTAGCC-3)
[52]. The genome copies in each sample were determined using
probe LDLR (5-FAM-TGCCAGGATGGCAAGTGCATCTCC-
TAMRA-3) and primers F-LDLR (5-CGTGCTCCCAGGAT-
GACTTC-3), and R-LDLR (5-CTCCATCACACACAAAC-
TGCG-3), all obtained from Applied Biosystems (Foster City,
CA). The standard curve was generated using L-mouse-LDLR (low-
density lipoprotein receptor) plasmid DNA carrying the LDLR gene
sequence between +9 to +69 inserted into pRRL-cPPT-X-PRE-SIN
[46]. The number of proviruses per genome in each sample was
calculated using the formula: copies of proviruses/copies of LDLR/2.
Each transgenic line was analyzed in triplicate.
Immunostaining of frozen muscle sections
Air-dried cryosections were rinsed with PBS and blocked with
2% normal goat serum. Sections were then incubated with rabbit
anti-EGFP antibody (1:1000; Molecular Probes, Eugene, OR),
and then with the secondary, Alexa488-anti-rabbit antibody
(1:1200; Molecular Probes). 49, 6-diamidino-2-phenylindole,
dihydrochloride was used for fluorescent nuclear staining (DAPI,
500 ng/ml; Molecular Probes) and the sections were mounted
with VECTASHIELD (Vector lab, Burlingame, CA). Stained
sections were observed using an optical fluorescence microscope
(DP70-WPCXP, Olympus, Tokyo, Japan).
Images and statistical analysis
Images of stained muscle sections were analyzed using Image J
(Version 1.43r, Wayne Rasband, National Institutes of Health).
The EGFP signals in each fiber type (Type I, IIA, IIB, IID/X)
were measured, and then averages (means 6 SEM) of signal
intensities in each fiber type were compared. Statistical analysis
was performed using a commercially available software package
(JMP, Version 8.0.2, SAS Institute Inc., USA). T-tests were used to
detect differences between groups. P- values ,0.005 indicated
statistically significant differences.
Supporting Information
Figure S1 LvMSCV-EGFP transgenic mouse muscle
showed fiber type-dependent variations in EGFP protein
expression. The serial sections of a soleus muscle from
LvMSCV-EGFP transgenic mouse expressed EGFP strongly in
both type I and type IIA (labeled I, A, respectively) fibers,
confirmed by immunofluorescent staining for myosin heavy chain
type I and type IIa, NADH-TR staining, and ATPase staining (at
pHs 10.8, 4.5, and 4.2). Bar represents 100 mm.
(TIF)
Table S1 Efficiency of embryo transduction with lenti-
viral vectors. The efficiency of generating Lv-mediated
transgenic mice is shown. The zona pellucida was removed from
two-cell-stage embryos of B6D2F1 mice, and they were transduced
with LvMSCV-EGFP at a multiplicity of infection of 105, then
transferred into 2.5-day pseudo-pregnant females. The existence of
transgenes was determined by PCR.
(DOC)
Methods S1 Immunofluorescent staining for fiber type
specific myosin heavy chains.
(DOC)
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